期刊文献+

2013年某院临床常见病原菌分布特点及耐药性分析 被引量:2

Distribution characteristics of common pathogens and resistance analysis of 2013
下载PDF
导出
摘要 目的分析2013年我院临床常见病原菌的分布特点及其对常见抗菌药物的耐药情况,为临床合理用药提供参考。方法利用VITEK-2全自动微生物分析仪和ATB自动微生物分析系统进行病原菌鉴定和药敏试验。结果5394株病原菌中,革兰氏阴性菌占53.58%,革兰氏阳性菌占23.88%,真菌占11.49%;大肠埃希菌、铜绿假单胞菌和肺炎克雷伯菌排在革兰氏阴性菌检出率的前三位,分别为:18.97%、12.44%、8.64%。MRSA和MRCNS的检出率是35.27%和81.37%。结论病原菌多重耐药情况严重,应引起临床高度重视。 Objective To understand distribution and drug resistance of common pathogens,so as to provide reference for the rational clinical application of antibiotics.Methods The implement identification was conducted by using VITEK-2 auto bacterial identification system,and susceptibility was tested by using susceptibility test instrument.The results were interpreted according to the standards developed by Clinical and Laboratory Standard Institute(CLSI) of the USA.Results A total of5394 strains of pathogens were isolated,including Gram-negative bacteria(53.58%),Gram-positive bacteria(23.88%) and fungi(11.49%).Escherichia coli,Pseudomonas aeruginosa and Klebsiella pneumoniae ranked in the top three detection rate of Gram-negative bacteria,respectively; 18.97%,12.44%,8.64%.MRSA and MRCNS detection rate was 35.27% and81.37%.Conclusion Multidrug-resistant pathogens in serious condition should lead to clinical attention.
作者 刘婉珊
出处 《广州医药》 2014年第4期57-60,共4页 Guangzhou Medical Journal
关键词 病原菌 抗菌药物 耐药性 合理用药 Pathogens Drug resistance Antibiotics Rational drug use
  • 相关文献

参考文献5

二级参考文献24

  • 1李耘,李家泰,王进,中国细菌耐药监测研究组.中国重症监护病房细菌耐药性监测研究[J].中华检验医学杂志,2004,27(11):733-738. 被引量:122
  • 2XIONG Zi-zhong ZHU De-mei WANG Fu ZHANG Ying-yuan.CTX-M-14, CTX-M-24 and resistance in Escherichia coli and Klebsiella pneumoniae clinical isolates[J].Chinese Medical Journal,2006(2):160-164. 被引量:13
  • 3Ivison ME, Mallela S. Increasing antimicrobial resistance:therapeutic implications for enterococcal infections[J]. Curr Infect Dis Rep, 2000, 2: 417-423.
  • 4Patel R, Rouse MS, Piper KE, et al. Linezolid therapy of vacomycin resistance Enterococcus faecium experimental endocarditis[J]. Antimicrob Agents Chemother, 2001, 45(2):621-623.
  • 5Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
  • 6Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
  • 7Falagas ME, Giannopoulou KP, Kokolakis GN, et al. Fosfo- mycin: use beyond urinary tract and gastrointestinal infec tions[J]. Clin Infect Dis, 2008, 46(7): 1069-1077.
  • 8Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis-emergence of resistance in aerobic faecal gram-negative bacteria of in patients, but not among strains causing infection after elective colorectal procedures [J ]. Scand J Infect Dis, 1993, 25(6) :725-733.
  • 9Andaker L, Burman LG, Eklund A, et al. Fosfomycin/met- ronidazole compared with doxycycline/metronidazole for the prophylaxis of infection after elective coloreetal surgery: a randomised double blind multicentre trial in 517 patients[J]. Eur J Surg, 1992, 158(3):181 185.
  • 10Nohr M, Andersen JC, Juul-Jensen KE. Prophylactic single dose fosfomycin and metronidazole compared with neomycin, haeitraein, metronidazole and ampicillin in elective colorectal operations[J]. Acta Chir Seand, 1990, 156(3):223-230.

共引文献883

同被引文献12

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部